TESARO, Inc. (NASDAQ:TSRO) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a report issued on Monday.

Other research analysts also recently issued reports about the company. Argus started coverage on TESARO in a research note on Friday, March 24th. They issued a “buy” rating and a $210.00 price objective on the stock. Citigroup Inc. reissued a “buy” rating and issued a $216.00 price objective (down from $232.00) on shares of TESARO in a research note on Saturday, April 22nd. Oppenheimer Holdings, Inc. set a $199.00 price objective on TESARO and gave the company a “buy” rating in a research note on Sunday, June 4th. Cann reissued a “buy” rating and issued a $199.00 price objective on shares of TESARO in a research note on Monday, June 5th. Finally, Credit Suisse Group set a $198.00 price objective on TESARO and gave the company a “buy” rating in a research note on Monday, June 5th. Two analysts have rated the stock with a sell rating, nine have given a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. TESARO currently has an average rating of “Buy” and a consensus target price of $173.74.

Shares of TESARO (NASDAQ:TSRO) traded down 4.25% during midday trading on Monday, hitting $120.81. The company’s stock had a trading volume of 1,247,071 shares. TESARO has a 1-year low of $83.26 and a 1-year high of $192.94. The company has a 50-day moving average price of $146.21 and a 200 day moving average price of $151.73. The company’s market cap is $6.51 billion.

TESARO (NASDAQ:TSRO) last announced its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($2.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.26) by $0.29. The business had revenue of $3.10 million during the quarter, compared to analyst estimates of $3.84 million. TESARO had a negative net margin of 910.35% and a negative return on equity of 96.49%. The firm’s revenue for the quarter was up 909.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($2.22) earnings per share. On average, equities research analysts predict that TESARO will post ($8.75) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.thecerbatgem.com/2017/07/17/valuengine-lowers-tesaro-inc-tsro-to-sell.html.

In other news, VP Edward C. English sold 8,500 shares of the company’s stock in a transaction that occurred on Tuesday, June 6th. The stock was sold at an average price of $138.65, for a total value of $1,178,525.00. Following the completion of the transaction, the vice president now directly owns 5,396 shares of the company’s stock, valued at $748,155.40. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 34.60% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in TSRO. Macquarie Group Ltd. raised its position in TESARO by 4.8% in the fourth quarter. Macquarie Group Ltd. now owns 301,510 shares of the biopharmaceutical company’s stock valued at $40,547,000 after buying an additional 13,830 shares in the last quarter. Shell Asset Management Co. raised its position in TESARO by 32.5% in the first quarter. Shell Asset Management Co. now owns 7,807 shares of the biopharmaceutical company’s stock valued at $1,201,000 after buying an additional 1,913 shares in the last quarter. Bellevue Group AG acquired a new position in TESARO during the first quarter valued at about $2,462,000. First Citizens Bank & Trust Co. acquired a new position in TESARO during the first quarter valued at about $288,000. Finally, First Trust Advisors LP acquired a new position in TESARO during the first quarter valued at about $3,993,000.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Stock Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related stocks with our FREE daily email newsletter.